Notice of Interim Results

RNS Number : 6102I

Futura Medical PLC

12 August 2019

 

Notice of Interim Results

12 August 2019

Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology and currently focused on sexual health and pain, will announce its interim results for the six months ended 30 June 2019 and provide a trading update on Wednesday 11 September 2019.

James Barder, Chief Executive Officer, Angela Hildreth, Finance Director/Chief Operating Officer and Ken James, Executive Director and Head of R&D, will host a presentation for analysts at 10am BST on the day of the results at the office of Liberum Capital at 25 Ropemaker Street, London, EC2Y 9LY.

Analysts wishing to attend the presentation should register their interest by emailing [e-mail].

A copy of the announcement will be made available on the Futura Medical website and following the results meeting a webcast of the presentation to analysts will also be made available within the Investor Centre section of the site.

For further information please contact:

Futura Medical plc 
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO

Email: [e-mail]
Tel: [phone]

Nominated Adviser and Sole Broker:
Liberum
Bidhi Bhoma/ Euan Brown/ Kane Collings
Tel: [phone]

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: [e-mail]

Tel: [phone]

Notes to editors:

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

The first European Phase 3 study for MED2005, referred to as "FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study of MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment of erectile dysfunction with an open label extension.  FM57 is progressing on track, with headline data expected by the end of 2019.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

 

END

 

 

NORSSLFDUFUSEIA